S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:AKRO

Akero Therapeutics - AKRO SEC Filings & 10K Form

$42.16
+0.62 (+1.49%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.34
$42.77
50-Day Range
$29.80
$46.50
52-Week Range
$7.52
$48.24
Volume
466,123 shs
Average Volume
639,041 shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.75

Recent Akero Therapeutics SEC Filings

DateFilerForm TypeView
12/05/2022
3:40 PM
Akero Therapeutics (Subject)
Skorpios Trust (Filed by)
Form SC 13G/A
12/05/2022
3:36 PM
Akero Therapeutics (Issuer)
Blue Horizon Enterprise Ltd (Reporting)
Ezbon International Ltd (Reporting)
Montrago Trustees Ltd (Reporting)
Skorpios Trust (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2022
4:52 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2022
4:48 PM
Akero Therapeutics (Issuer)
Harrison Seth Loring (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2022
6:15 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2022
4:26 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/09/2022
1:21 PM
Akero Therapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G
11/04/2022
6:31 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2022
6:22 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/02/2022
8:52 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/01/2022
4:38 PM
Akero Therapeutics (Issuer)
Harrison Seth Loring (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2022
8:50 PM
Akero Therapeutics (Issuer)
Harrison Seth Loring (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2022
8:27 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2022
8:25 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2022
8:23 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4/A
10/17/2022
4:40 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/12/2022
3:59 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2022
5:00 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/05/2022
7:55 AM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2022
7:57 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2022
9:16 AM
Akero Therapeutics (Subject)
Avidity Partners Management LP (Filed by)
Form SC 13G
09/15/2022
6:59 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2022
6:59 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2022
6:57 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2022
6:56 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2022
4:16 PM
Akero Therapeutics (Filer)
Form 424B5
09/15/2022
4:00 PM
Akero Therapeutics (Subject)
venBio Global Strategic Fund II L.P. (Filed by)
Form SC 13D/A
09/13/2022
8:16 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2022
8:15 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2022
8:14 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2022
8:14 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2022
8:13 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2022
4:11 PM
Akero Therapeutics (Filer)
Form 424B5
09/13/2022
8:07 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2022
3:17 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2022
3:19 PM
Akero Therapeutics (Subject)
PFIZER INC (Filed by)
Form SC 13G
06/16/2022
6:14 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2022
5:52 AM
Akero Therapeutics (Filer)
Form 424B5
06/08/2022
8:06 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2022
3:06 PM
Akero Therapeutics (Issuer)
Henderson Jane (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2022
3:06 PM
Akero Therapeutics (Issuer)
Xu Yuan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2022
6:31 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2022
6:26 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2022
3:23 PM
Akero Therapeutics (Filer)
Form DEF 14A
09/03/2021
3:37 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2021
8:15 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2021
6:31 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/13/2021
6:04 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2021
4:39 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/04/2021
4:38 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2021
3:09 PM
Akero Therapeutics (Issuer)
Judy Chou (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2021
3:08 PM
Akero Therapeutics (Issuer)
Judy Chou (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
07/14/2021
7:19 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2021
6:19 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2021
3:51 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/21/2021
7:15 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2021
7:07 PM
Akero Therapeutics (Issuer)
Bitterman Kevin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:59 PM
Akero Therapeutics (Issuer)
Heyman Tomas J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:58 PM
Akero Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:58 PM
Akero Therapeutics (Issuer)
Henderson Jane (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:57 PM
Akero Therapeutics (Issuer)
Xu Yuan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:56 PM
Akero Therapeutics (Issuer)
Harrison Seth Loring (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:56 PM
Akero Therapeutics (Issuer)
Bitterman Kevin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
4:55 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2021
3:13 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/02/2021
3:06 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2021
5:01 AM
Akero Therapeutics (Filer)
Form S-3ASR
05/13/2021
6:30 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2021
6:18 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/27/2021
3:15 PM
Akero Therapeutics (Filer)
Form DEF 14A
04/26/2021
4:09 PM
Akero Therapeutics (Issuer)
Xu Yuan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/26/2021
4:08 PM
Akero Therapeutics (Issuer)
Xu Yuan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/26/2021
7:05 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/13/2021
7:30 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/23/2021
7:10 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/16/2021
7:30 AM
Akero Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/16/2021
7:10 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/12/2021
4:25 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/02/2021
4:56 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/11/2021
2:50 PM
Akero Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
Form SC 13G/A
01/11/2021
6:57 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
6:54 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
6:01 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2021
5:48 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2020
3:53 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2020
3:19 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2020
7:53 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2020
7:52 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2020
7:50 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2020
7:49 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2020
7:47 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/16/2020
5:30 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2020
3:20 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2020
7:30 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2020
3:54 PM
Akero Therapeutics (Issuer)
Bitterman Kevin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2020
1:14 PM
Akero Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
Form SC 13G/A
09/09/2020
4:26 PM
Akero Therapeutics (Subject)
venBio Global Strategic Fund II L.P. (Filed by)
Form SC 13D/A
08/12/2020
3:50 PM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2020
3:25 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2020
4:16 PM
Akero Therapeutics (Filer)
Form RW
This page (NASDAQ:AKRO) was last updated on 12/8/2022 by MarketBeat.com Staff